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cycle, independently of its on-target effect
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ABSTRACT
The small-molecule inhibitor of phosphoglycerate dehydrogenase, NCT-503, reduces incorporation of glu-
cose-derived carbons into serine in vitro. Here we describe an off-target effect of NCT-503 in neuroblast-
oma cell lines expressing divergent phosphoglycerate dehydrogenase (PHGDH) levels and single-cell
clones with CRISPR-Cas9-directed PHGDH knockout or their respective wildtype controls. NCT-503 treat-
ment strongly reduced synthesis of glucose-derived citrate in all cell models investigated compared to the
inactive drug control and independent of PHGDH expression level. Incorporation of glucose-derived car-
bons entering the TCA cycle via pyruvate carboxylase was enhanced by NCT-503 treatment. The activity
of citrate synthase was not altered by NCT-503 treatment. We also detected no change in the thermal sta-
bilisation of citrate synthase in cellular thermal shift assays from NCT-503-treated cells. Thus, the direct
cause of the observed off-target effect remains enigmatic. Our findings highlight off-target potential
within a metabolic assessment of carbon usage in cells treated with the small-molecule inhibitor,
NCT-503.
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Neuroblastoma is the most common extracranial paediatric solid
tumour that arises from precursor cells in the developing sympa-
thetic nervous system. Amplification of the MYCN oncogene
among other molecular features, increase neuroblastoma aggres-
siveness and risk for relapse1. Directly targeting MYCN remains a
challenge due to its nuclear localisation, the lack of a ligand bind-
ing site and its diverse physiological functions in the maintenance
of normal tissues2. Indirect approaches targeting metabolic altera-
tions driven by high-level MYCN amplification recently identified
an enhanced dependency of these cells on the serine-glycine one-
carbon metabolic pathway3. This network generates one-carbon
units that are utilised in various metabolic reactions, including
nucleotide biosynthesis, methylation reactions and maintaining
redox balance. Cells produce one-carbon units from serine, which
can either be imported or synthesised de novo through the rate-
limiting enzyme, phosphoglycerate dehydrogenase (PHGDH). It is
well appreciated that the small-molecule PHGDH inhibitor, NCT-
503, reduces production of glucose-derived serine and attenuates
the growth of PHGDH-dependent cell lines and xenograft
tumours4. In recent work, we have shown that NCT-503 reduces
proliferation in vitro and initial tumour growth in vivo in MYCN-
amplified neuroblastoma cells5. Here we assessed proliferation
and applied pulsed stable isotope-resolved metabolomics utilising
13C-glucose labelling6 in cellular models for neuroblastoma
expressing varying levels of the NCT-503 target, PHGDH, with the




The BE(2)-C (RRID: CVCL_V006) cell line was obtained from ECACC
(Salisbury, UK) and the Kelly (RRID: CVCL_2092) cell line from the
DSMZ (Braunschweig, Germany). The SK-N-AS (RRID: CVCL_1700)
cell line was kindly provided by J. Schulte (Charite, Berlin,
Germany) and the SH-EP (RRID: CVCL_0524) cell line by L.
Savelyeva (DKFZ, Heidelberg, Germany). CRISPR/Cas9-mediated
PHGDH knockout-clones were generated as described5. In brief,
the plasmids, px459_PH_ex4_80 (clone #11) or px459_PH_ex7_96
(clone #38), were transfected into BE(2)-C cells using the Effectene
(Qiagen, Hilden, Germany) method according to the manufac-
turer’s directions. These plasmids encode for SpCas9 and a gRNA
targeting PHGDH exon 4 (50-TGCCGGAAGATCTTGCAAGA-30) or
PHGDH exon 7 (50-CTTCATCGAAGCCGTCGCCT-30). Control cells
were transfected with the px459 vector, which expresses SpCas9
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(pSpCas9(BB)-2A-Puro; #48139, Addgene, Watertown, MA, USA).
After 24 h, 2mg/ml puromycin (Thermo Fisher Scientific, Waltham,
MA, USA) was added to the culture medium for 72 h to enrich for
positively transfected cells. Thereafter, limited dilution assays were
performed by seeding 0.5–1 cell per well into 96-well plates. All
expandable single-cell clones were subjected to western blotting
and pulsed stable isotope-resolved metabolomics coupled to GC-
MS to identify PHGDH knockouts. Cell lines were maintained at
37 C and 5% CO2 in DMEM (Thermo Fisher Scientific, Waltham,
MA, USA) medium lacking glucose, glutamine, sodium pyruvate
and phenol red and supplemented with 10% foetal calf serum
(Merck, Darmstadt, Germany), 2.5 g/L glucose (Merck, Darmstadt,
Germany) and 2mM glutamine (Thermo Fisher Scientific, Waltham,
MA, USA). Cell lines were maximally cultured up to passage 28.
Cell lines were authenticated by high-throughput SNP-based
assays7 and weekly monitored for mycoplasma infections using
PlasmoTestTM (InvivoGen, San Diego, CA, USA) according to the
manufacturer’s instructions.
Drug source and preparation
N-(4,6-Dimethylpyridin-2-yl)-4-(4-(trifluoromethyl)benzyl)piperazine-
1-carbothioamide, the NCT-503 small molecule inhibitor (SML1659,
Sigma-Aldrich, St. Louis, MO, USA) and N-(4,6-dimethylpyridin-2-
yl)-4-pyridin-4-ylpiperazine-1-carbothioamide, the inactive NCT-503
control (SML1671, Sigma-Aldrich, St. Louis, MO, USA) were first
described by Pacold et al.4. The 4-trifluoromethyl substituent of
NCT-503 was replaced with a 4-pyridinyl group resulting in the
inactive NCT-503 control compound that did not inhibit PHGDH4,
which was used as the inactive drug control in this study. NCT-
503 and inactive NCT-503 control were dissolved in DMSO for
9.9mM and 15.3mM stock solutions, which were aliquoted and
stored at 4 C until use. Cells were treated with 10 mM of either
compound diluted in culture medium.
Western blotting
Cells were lysed for western blotting in buffer containing 20mM
Tris-HCl, 7M urea, 0.01% Triton X-100, 100mM DTT, 40mM MgCl2
and CompleteVR protease inhibitor cocktail, and proteins separated
by 12% SDS-PAGE then semi-dry blotted polyvinylidene difluoride
membranes (Roche, Basel, Switzerland) probed with a mouse
monoclonal antibody against GAPDH (MAB374, clone 6C5, Merck,
Darmstadt, Germany, RRID:AB_2107445) and a rabbit polyclonal
antibody against PHGDH (#13428, Cell Signalling, Danvers, MA,
USA, RRID:AB_2750870). Band density was analysed using
VisionCapt software, version 16.11a (Vilber Lourmat, Eberhardzell,
Germany) on western blots, and results were normalised to the
respective loading controls.
Proliferation assay
Cell viability and number were measured with the VI-CELL-XR Cell
Viability Analyser (Beckman Coulter, Brea, CA, USA) based on the
Trypan blue exclusion method8.
Pulsed stable isotope-resolved metabolomics and GC-
MS analysis
Cells were seeded as indicated for labelling experiments, and
medium change was performed 4 h before harvest6. A second
medium change was performed 10min before harvest to expose
cells to media supplemented with either 2.5 g/L 13C-glucose or
2.5 g/L12C-glucose, the latter representing the natural mass iso-
topic distribution. Cells were washed with HEPES buffer (140mM
NaCl, 5mM HEPES, pH 7.4) containing labelled or non-labelled glu-
cose and quenched by adding 50% ice-cold methanol containing
2 mg/ml cinnamic acid (Merck, Darmstadt, Germany) as an internal
control. Metabolite extraction was performed as described9. In
brief, polar metabolites were extracted by methanol/chloroform/
water extraction, centrifuged at 4000g for 10min at 4 C and dried
in a vacuum concentrator overnight. For GC-MS measurement,
extracts were dissolved in methoxyamine hydrochloride solution
(40mg/mL MeOX in pyrimidine) at 30 C for 90min with constant
shaking followed by an incubation at 37 C for 60min with N-
methyl-N-[trimethylsilyl] trifluoroacetamide containing an alkane
mixture. Extracts were centrifuged at maximum speed for 10min,
and aliquots were transferred into glass vials for GC-MS measure-
ment. Metabolite analysis was performed on a Q Exactive GC
Orbitrap system (Thermo Fisher Scientific, Waltham, MA, USA).
Samples were injected in 1:10 split mode with an injection volume
of 1mL in a temperature controlled injector (TriPlus RSH autosam-
pler, Thermo Fisher Scientific, Waltham, MA, USA) with baffled
glass liner (Thermo Fisher Scientific, Waltham, MA, USA). The injec-
tion temperature was kept at 80 C for 15 s, then increased to
260 C with a ramp of 7 C/s and kept at 260 C for 3min. Gas
chromatographic separation was performed on a Thermo
Trace1300 GC system (Thermo Fisher Scientific, Waltham, MA,
USA), equipped with a TG-5SILMS column (30m length, 0.25mm
inner diameter, 0.25 mm film thickness). Helium was used as carrier
gas with a flow rate of 1.2ml/min. Gas chromatography was per-
formed with the following program: initial temperature of 67.5 C
for 2min, 1st ramp to 120 C with 7 C/min, 2nd ramp to 200 C
with 9 C/min, 3rd ramp to 330 C with 12 C/min and final hold at
350 C for 6min. Spectra were acquired in the range from 65 to
600m/z, with a resolution of 30,000 (at m/z 200). GC-MS chroma-
tograms were processed with Xcalibur Quan Browser 4.3 software,
and the identity of the analysed metabolites was verified by
standards as described10.
Citrate synthase activity assay
Cells were treated for 24 h with 10mM NCT-503 or inactive NCT-
503 control, and then lysed in CelLytic M provided in the citrate
synthase assay kit (CS0720, Sigma-Aldrich, St. Louis, MO, USA).
Aliquots of whole-cell extract containing equal total protein
amounts were used for the citrate synthase activity assay accord-
ing to the manufacturer’s instructions. Total protein was assessed
by colorimetric protein quantification based on the Bradford assay,
ROTIVR Quant (Carl Roth, Karlsruhe, Germany).
Acetyl-coenzyme A assay
Cells were treated for 48 h with 10mM NCT-503 or inactive NCT-
503 control. Aliquots with equal numbers of cells were analysed
by the acetyl-coenzyme A (acetyl-CoA) assay kit (MAK039, Sigma-
Aldrich, St. Louis, MO, USA) according to the manufacturer’s
instructions.
Cellular thermal shift assay
Cells were treated for 48 h with 10mM NCT-503 or inactive NCT-
503 control, scraped from the culture plates using a policeman for
the cellular thermal shift assay as previously described11 using a
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rabbit polyclonal antibody against PHGDH (#13428, Cell Signalling,
Danvers, MA, USA, RRID:AB_2750870) and a rabbit monoclonal
antibody against citrate synthase (#14309, Cell Signalling, Danvers,
MA, USA, RRID:AB_2665545). Band density on western blots was
analysed using VisionCapt software, version 16.11a (Vilber
Lourmat, Eberhardzell, Germany), and data was normalised by set-
ting the highest and lowest value in each dataset to 100% and
0%, respectively.
Statistical analysis
Statistical analysis was performed using the GraphPad Prism (ver-
sion 7, GraphPad Software, La Jolla, CA, USA) and R-studio (version
1.1.383) software packages with R version 3.4.012. If not stated
otherwise, a two-tailed Student’s t-test with Welch’s correction
was applied to test significance of differences between test-
ing groups.
Results
NCT-503 reduces viability of cells expressing low target
enzyme levels
We have previously shown that NCT-503 treatment reduces prolif-
eration of neuroblastoma cells expressing high PHGDH levels in
vitro and initially reduces patient-derived neuroblastoma xenograft
tumour volumes in mice5. By random observation, we noticed
that NCT-503 treatment also attenuated proliferation of neuro-
blastoma cells expressing low PHGDH levels. We extended prolif-
eration monitoring to a panel of two neuroblastoma cell lines
each expressing either high-level (BE(2)-C and Kelly) or low-level
(SH-EP and SK-N-AS) PHGDH (Figure 1(A)). NCT-503 treatment sig-
nificantly decreased the number of viable cells in all four cell lines
compared to cultures treated with the inactive drug control
(Figure 1(B)). Viable BE(2)-C and SH-EP cells were reduced to
50–60% of controls and viable Kelly and SK-N-AS cells by 65–80%
of controls, demonstrating no clear dependency on target expres-
sion level in the cell lines and a broad range of 20–50% reduction
in viability in all cell lines tested. These data indicate that NCT-503
is effective in a PHGDH-independent manner in neuroblastoma
cells, raising the possibility that some part of NCT-503 action may
be caused by off-target effects.
NCT-503 treatment reduces carbon flow into the TCA cycle
Since PHGDH catalyses the rate-limiting step in serine synthesis,
we performed metabolic analyses in neuroblastoma cells to inves-
tigate the effects of NCT-503 treatment on cellular metabolism.
Glucose-derived carbon usage was traced using pulsed stable iso-
tope labelling with 13C-glucose followed by quantitative metabo-
lomics analysis. Incorporation of glucose-derived carbons into
serine was significantly reduced upon NCT-503 treatment of BE(2)-
C cells (high-level PHGDH), but not detectable in SH-EP cells (low-
level PHGDH, Figure 2(A)), demonstrating that on-target effects
were sensitive to the target level in the cells. NCT-503 treatment
did not modulate incorporation of glucose-derived carbons into
pyruvate in either cell line (Figure 2(A)). However, significantly less
13C-glucose was incorporated into citrate upon NCT-503 treatment
of BE(2)-C and SH-EP cells compared to cells treated with the
inactive drug control (Figure 2(B)). Incorporation of glucose-
derived carbons into malate was significantly enhanced (Figure
2(B)), while acetyl-CoA levels remained stable after NCT-503 treat-
ment in BE(2)-C and SH-EP cells compared to the respective con-
trols (Figure 2(C)). These data demonstrate that besides the on-
target inhibition of PHGDH directing glucose-derived carbons into
serine, NCT-503 also reduces conversion of pyruvate into citrate
while elevating the conversion of pyruvate into malate.
Reduced carbon flow into the TCA cycle is an off-target NCT-
503 effect
To test whether the lack of efficient conversion of pyruvate into
citrate was due to the NCT-503 compound rather than PHGDH
inhibition, we turned to our two PHGDH knockout cell clones gen-
erated using CRISPR/Cas9 technology from the BE(2)-C cell line.
Knockout of PHGDH enzyme activity was validated on the protein
level (Figure 3(A)) and in the cell clone metabolome (Figure 3(B))5.
PHGDH knockout did not affect incorporation of glucose-derived
carbons into pyruvate, citrate or malate (Figure 3(B)). Glucose-
derived carbons were similarly incorporated into pyruvate in
Figure 1. NCT-503 treatment inhibits proliferation of neuroblastoma cells with low target enzyme expression. (A) Western blot analysis of PHGDH expression in a panel
of four neuroblastoma cell lines. GAPDH served as loading control. (B) Proliferation assay indicating the number of viable BE(2)-C, Kelly, SH-EP and SK-N-AS cells treated
with 10mM NCT-503 or inactive drug control (inactive NCT-503) for 96 h (mean±SD, n¼ 3). p 0.001.
1284 B. ARLT ET AL.
PHGDH knockout clones treated with either NCT-503 or the
inactive drug control (Figure 3(C)). However, NCT-503 treatment
diminished glucose-derived 13C-incorporation into citrate, in line
with considerably higher label incorporation into malate and the
stable acetyl-CoA levels (Figure 3(D,E)). We conclude that NCT-503
triggers metabolic remodelling in neuroblastoma cells, independ-
ent of PHGDH expression.
Off-target activity is not acting via citrate synthase
We next investigated whether rerouteing glucose-derived carbons
into the TCA cycle is based on NCT-503-mediated inhibition of cit-
rate synthase, which converts oxaloacetate and acetyl-CoA into
citrate. Citrate synthase activity was colorimetrically assessed in
whole-cell lysates of the both PHGDH knockout clones and the
BE(2)-C cell line. No significant changes in citrate synthase activity
were measured between extracts from knockout clones and the
parental cell line or between extracts from cultures treated with
NCT-503 or the inactive drug control (Figure 4(A)). We also
assessed target engagement by the drug using the cellular ther-
mal shift assay11, which assesses thermal stabilisation of proteins
caused or changed by drug binding. The melting curves represent
the relative protein band intensities of PHGDH and citrate syn-
thase after treatment with NCT-503 or the inactive drug control in
BE(2)-C cell lysates as a function of temperature, and demon-
strated a thermal shift in PHGDH but not in citrate synthase
(Figure 4(B)). The clear shift was between the NCT-503-PHGDH
aggregation temperature of 56.5 C and the inactive drug control-
PHGDH aggregation temperature of 53.5 C (Figure 4(B)). The NCT-
503-citrate synthase aggregation temperature was 54 C while the
inactive drug control-PHGDH aggregation temperature was
54.5 C, thus, indicating no major changes in thermal stability of
citrate synthase by NCT-503 treatment (Figure 4(B)). Our data
demonstrate a novel mode of action for NCT-503, which limits
glucose-derived carbon entry into citrate from pyruvate in neuro-
blastoma cells (Figure 4(C)). We propose that cells may adapt to
this metabolic alteration by increased routeing of glucose-derived
carbons from pyruvate into malate as an alternative pathway to
support glucose-derived TCA cycle anaplerosis.
Discussion
The current state of knowledge about the small molecule inhibi-
tor, NCT-503, is that it selectively inhibits PHGDH, the rate-limiting
enzyme in glucose-derived serine synthesis and is used to study
serine synthesis through PHGDH in various cancer entities3,13. We
identified an off-target effect of NCT-503 in a pulsed stable iso-
tope-resolved metabolomics approach6 utilising 13C-glucose in
neuroblastoma cell lines and genetically engineered PHGDH
knockout clones. NCT-503 strongly reduced glucose-derived citrate
synthesis in neuroblastoma cell lines, in line with increased incorp-
oration of glucose-derived carbons entering the TCA cycle from
pyruvate into malate. Carbon flow into the TCA cycle was inde-
pendent of PHGDH level in the cells. This observed off-target
effect was not acting via alterations in citrate synthase activity,
but the exact mechanism employed in this off-target effect
remains enigmatic.
NCT-503 treatment reduced the number of viable SH-EP and
SK-N-AS cells expressing low-level PHGDH by up to 50% com-
pared to cells treated with inactive drug control in our study.
Similarly, Xia et al. recently reported that treating SK-N-AS and SH-
SY5Y neuroblastoma cell lines, both with low-level PHGDH expres-
sion, with 10mM NCT-503 reduced proliferation by up to 20%
compared to controls3. Pacold et al. also described an anti-
Figure 2. NCT-503 treatment reduces the carbon flow into citrate in the TCA cycle. BE(2)-C and SH-EP cells were seeded, cultured for 48 h with 10mM NCT-503 or
inactive drug control and maintained in medium containing fully labelled 13C-glucose (13mM) for 10min before harvest. Shown are the percentages of 13C-label
incorporation into serine and pyruvate (A), citrate and malate (B) and the quantification of acetyl-CoA levels (C). p 0.01; p 0.001.
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proliferative effect for the same NCT-503 concentration when
treating a metastatic breast cancer cell line with low-level PHGDH
expression, MDA-MB-2314. This response pattern in additional cell
lines with low target levels obtained in two independent studies,
which is characterised by a comparatively weaker but detectable
anti-proliferative effect, corroborates our own data and may be
explained by our observed off-target effect of NCT-503. However,
NCT-503 treatment did not reduce proliferation in the ZR-75-1
breast carcinoma cell line and the SK-MEL-2 malignant melanoma
cell line, which both express low PHGDH levels4, suggesting that
phenotypic consequences of the off-target effect described here
vary among cell lines. Cellular metabolism is, among other factors,
highly influenced by its genetic background14. Individual onco-
genes and tumour suppressors specifically influence metabolic
Figure 3. Altered carbon flow into the TCA cycle is an off-target effect of NCT-503. (A) Western blot analysis of PHGDH expression in PHGDH knockout clones #11 and
#38. GAPDH served as loading control. (B) PHGDH knockout clones #11 and #38 and the respective control cells were seeded and maintained in medium containing
fully labelled 13C glucose (13mM) for 10min before harvest. Shown are the percentages of 13C-label incorporation into serine, pyruvate, citrate and malate. (C–E)
PHGDH knockout clones #11 and #38 and the respective control cells were seeded, cultured for 48 h with 10mM NCT-503 or the inactive drug control and maintained
in medium containing fully labelled 13C glucose (13mM) for 10min before harvest. Shown are the percentages of 13C-label incorporation into serine and pyruvate (C),
citrate and malate (D) and the quantification of acetyl-CoA levels (E). p< 0.05; p 0.01; p 0.001.
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circuitry15, and could compensate for the NCT-503 treatment-
mediated reduction in glucose-derived citrate synthesis so that
fundamental processes in cancer cells, such as proliferation, are
not detectably altered. Cancer cells are characterised by a high
level of metabolic adaptability, and interact with non-transformed
cells within their respective microenvironment to survive and pro-
liferate in poorly perfused niches where nutrients are rare16. Data
showing that the low-level PHGDH expressing MDA-MB-231 cells,
which were weakly responsive to NCT-503 treatment in vitro, were
non-responsive when grown as xenografted tumours in mice4
points towards the importance of the tumour microenvironment
and should be investigated in future studies. Altogether, the off-
target effect described in this study might explain the sensitivity
of certain cells expressing low PHGDH levels towards NCT-
503 treatment.
By applying pulsed stable isotope-resolved metabolomics, we
observed a decrease in glucose-derived carbons into serine as
well as a rerouteing of glucose-derived carbons entering the TCA
cycle in neuroblastoma cells treated with NCT-503. While blockage
of glucose-derived carbon incorporation into serine and glycine in
NCT-503-treated cells has already been studied in detail3,4, conver-
sion of glucose-derived carbons into TCA cycle intermediates
under NCT-503 treatment has not been addressed in detail. Reid
et al. used kinetic flux profiling17,18 with 13C-glucose labelling to
directly measure flux into metabolic pathways, and demonstrated
that 25mM NCT-503 reduced flux through the pentose phosphate
pathway and TCA cycle, including a reduced fraction into citrate/
isocitrate, in epithelial cancer cells13. Treatment of these cells with
another PHGDH inhibitor, PKUMDL-WQ-210119, induced similar
reductions in metabolic flux. PHGDH knockout clones were used
to confirm that the observed kinetic profiles upon PKUMDL-WQ-
2101 treatment were not due to off-target effects13. However, kin-
etic flux profiling in NCT-503 treated PHGDH knockout clones has
not been reported13. Our data obtained with NCT-503-treated
Figure 4. Citrate synthase activity and protein stability are not altered by NCT-503 treatment in neuroblastoma cells. (A) PHGDH knockout clones #11, #38 and the
respective control cells were seeded, treated with 10mM NCT-503 or inactive drug control for 24 h and assessed for citrate synthase activity. (B) Wildtype BE(2)-C cells
were seeded, treated with 10mM NCT-503 or inactive drug control for 48 h and subjected to cellular thermal shift assays followed by western blotting of PHGDH and
citrate synthase expression. (C) Schematic model summarising the NCT-503 treatment-mediated effects in neuroblastoma cells.
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PHGDH knockout neuroblastoma cell clones demonstrates that the
reduced incorporation of glucose-derived carbons into citrate is
completely independent of the expression of PHGDH itself and,
thus, due to an off-target effect of NCT-503. Future studies with
newly emerging PHGDH inhibitors are required to investigate
whether the reduced flux into citrate/isocitrate observed with
PKUMDL-WQ-210113 represents a common on-target effect of the
class of PHGDH inhibitors.
We have shown that 13C-glucose incorporation rates into pyru-
vate were similar between cells treated with NCT-503 or the
inactive drug, but incorporation rates into citrate were signifi-
cantly reduced in all NCT-503-treated cell lines. Citrate synthase
catalyses the first step of the TCA cycle20 and is upregulated in
several cancer types21,22. Since pyruvate is converted into acetyl-
CoA and subsequently into citrate via the pyruvate dehydrogen-
ase complex and citrate synthase, we analysed whether citrate
synthase could be a possible NCT-503 target. NCT-503, surpris-
ingly, did not alter citrate synthase activity in vitro or the thermal
stability of the enzyme, indicating that the reduction in glucose-
derived carbon incorporation into citrate induced by NCT-503
treatment is not caused by direct inhibition of citrate synthase
activity or stable binding by NCT-503 that alters the thermo-
dynamic properties of the enzyme. Thus, the underlying mechan-
ism remains unclear. Besides diminished routeing of glucose-
derived carbons from pyruvate into citrate, we observed enhanced
routeing of glucose-derived carbons from pyruvate into malate in
BE(2)-C and SH-EP cells as well as two PHGDH knockout clones by
NCT-503 treatment. These data suggest a shift from citrate syn-
thase to enhanced usage of the pyruvate carboxylase pathway for
TCA cycle anaplerosis. Pyruvate carboxylase requires acetyl-CoA as
an allosteric activator23 that was expressed at steady levels in our
NCT-503-treated cells. We propose that NCT-503 treatment enhan-
ces pyruvate carboxylase pathway activity in neuroblastoma cells
as an alternative route to fuel the TCA cycle with glucose-derived
carbons. Activation of pyruvate carboxylase was first described by
Fan et al. in human non-small cell lung cancer24. Cheng et al.
found that glutaminase-silenced glioblastoma cells induce a com-
pensatory anaplerotic mechanism catalysed by pyruvate carboxyl-
ase to use glucose-derived pyruvate rather than glutamine for
anaplerosis25, thus, demonstrating the high flexibility of cancer
cells to circumvent perturbations in their metabolic networks.
Off-target effects are a common theme in pharmacology. For
example, the MEK-inhibitors, PD98059 and U0126, were recently
reported not only to inhibit calcium entry into cells but also affect
AMPK activity independent of their on-target effect on MEK1/
226,27. Nevertheless, these compounds are intensely studied in
clinical trials and continue to be routinely used in preclinical mod-
els to pharmacologically modulate MAPK/ERK signalling. The small
molecule inhibitor, NCT-503, not only targets PHGDH, the rate lim-
iting enzyme in de novo serine synthesis, but also induces a
remodelling of glucose-derived carbon flow into the TCA cycle
independently of PHGDH expression in neuroblastoma cells. At
this stage, we can only speculate whether the substantial anti-
tumour activity reported by us and others in preclinical models of
several cancer types could at least partly be due to reduced
incorporation of glucose-derived carbons into citrate. The data
presented here emphasises the importance to preclinically charac-
terise the molecular actions of NCT-503 in detail in the potential
target cancers of interest in future studies.
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